AF
Antonio F. Santidrian, PharmD, Ph.D.
Chief Scientific Officer and Head of Technical Operations
Calidi BiotherapeuticsTherapeutic Areas
Calidi Biotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CLD-401 | Multiple Solid Tumors | IND-Enabling |
| CLD-501 | Myeloma, Autoimmune | Discovery |
| CLD-601 | Oncology (undisclosed) | Discovery |
| NeuroNova | Relapsed/Refractory Glioblastoma | Phase 2 |
| SuperNova (CLD-201) | TNBC, SCCHN, Sarcoma | Phase 1 |
Leadership Team at Calidi Biotherapeutics
EP
Eric Poma, Ph.D.
Chief Executive Officer and Director
AJ
Andrew Jackson
Chief Financial Officer
GT
Guy Travis Clifton, M.D.
Chief Medical Officer
JA
James A. Schoeneck
Chairman of the Board
GE
George E. Peoples, M.D., FACS
Board Member